Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 324
- Registration Number
- NCT06643819
- Locations
- 🇰🇷
Wonju Severance Christian Hospital, Wonju, Korea, Republic of
Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06536309
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Sichuan Academy of Medical Sciences
- Target Recruit Count
- 297
- Registration Number
- NCT06501651
- Locations
- 🇨🇳
Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05681273
- Locations
- 🇨🇳
Zhongshan hospital, Shanghai, China
Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2022-09-19
- Target Recruit Count
- 138
- Registration Number
- NCT05545059
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients with Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 320
- Registration Number
- NCT05528419
- Locations
- 🇨🇳
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 957
- Registration Number
- NCT05359068
- Locations
- 🇨🇳
Beijing Pinggu Hospital, Beijing, Beijing, China
🇨🇳Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇨🇳Liuzhou people's Hospital, Liuzhou, Guangxi, China
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
- Conditions
- Interventions
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 30
- Registration Number
- NCT05194111
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
24 Hour Ambulatory Cardiac Oxygen Consumption
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 26
- Registration Number
- NCT05170061
- Locations
- 🇺🇸
Erie County Medical Center, Buffalo, New York, United States
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
- Conditions
- Interventions
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 716
- Registration Number
- NCT05056727
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.